Ropeginterferon alfa-2b (BESREMi®)
Polycythemia Vera (PV)
Key Facts
About PharmaEssentia
PharmaEssentia's mission is to build a global leader in hematologic oncology by unlocking the therapeutic potential of interferons through innovative molecular engineering. Its key achievement is the successful global commercialization of BESREMi®, the first FDA-approved interferon for polycythemia vera (PV), marking a significant milestone for Taiwan's biotech sector. The company's strategy leverages a fully integrated model—from R&D and manufacturing to global commercialization—to expand its lead in MPNs and explore new indications. Following its 2024 IPO, PharmaEssentia is positioned to scale its operations and advance a promising pipeline.
View full company profileTherapeutic Areas
Other Polycythemia Vera (PV) Drugs
| Drug | Company | Phase |
|---|---|---|
| SLN124 | Silence Therapeutics | Phase 2 |